Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-12-05
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well daratumumab after a stem cell transplant works in
treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill
cancer cells that are left after chemotherapy.